Jane is the Foundation Director of the Australian Centre for Behavioural Research in Diabetes (ACBRD), established in 2010 as a partnership for better health between Diabetes Victoria and Deakin University. She has a PhD in health psychology from Royal Holloway, University of London, is a chartered psychologist, a Fellow of the British Psychological Society and a Fellow of the Royal Society of Medicine.
Jane’s research translation achievements include being a founding member of the DAFNE (‘dose adjustment for normal eating’) education program, which has trained more than 43,500 adults with type 1 diabetes in the UK since 2001, more than 3,200 in Australia/New Zealand since 2005 (OzDAFNE), and is also available in Kuwait and Singapore. On behalf of Diabetes Australia, she is the NDSS Leader for the Mental Health and Diabetes National Priority Area, and also for the Starting Insulin in Type 2 Diabetes National Priority Area. Though the Mental Health Priority Area, she has co-authored the NDSS ‘Diabetes and Emotional Health‘ Handbook and Toolkit (2016), which has now been adapted as a Practical Guide for the UK healthcare context by Diabetes UK (2019). In 2011, Jane led the development of the Diabetes Australia position statement: ‘A new language for diabetes’, which has ignited an international movement (#LanguageMatters) focused on improving the language used in communicating with and about people with diabetes, with similar statements now produced by the IDF (2014), ADA/AADE (2017), and NHS England/Diabetes UK (2018). In 2017, she led the development of a Diabetes Australia position statement: ‘Glucose self-monitoring in adults with type 1 or type 2 diabetes’. Her diabetes stigma research has led to global interest in this issue, influencing advocacy and campaigns, and many requests for translation/use of the DSAS-1 and DSAS-2 measures to enable similar research in other countries (e.g. China, Denmark, Japan, New Zealand, Turkey, UK, USA). In 2018, she was honoured to be the subject of a Lancet Diabetes & Endocrinologyprofile: ‘Jane Speight: tackling diabetes and its stigma Down Under’. In 2019, this profile was among 33 featured by The Lancet in a virtual collection to mark International Women’s Day: #LancetWomen. Jane has also contributed to chapter 2 (emotional wellbeing) of the 2018 International evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Jane leads a large and varied program of research in Australia, with established and ongoing international collaborations (particularly in the UK and Denmark), through which she aims to improve the quality of life and self-care of people with diabetes, and encourage healthcare professionals to better understand the impact of diabetes and its treatment from the individual’s perspective. Her principle research interests focus on developing, evaluating and enhancing provision of structured diabetes education; restoring awareness of hypoglycaemia and preventing recurrent severe hypoglycaemia; expectations, experiences and optimisation of new diabetes treatments and technologies; the experience of social stigma related to diabetes; monitoring and reducing diabetes-related distress; investigating the needs of specific populations, e.g. young adults with type 2 diabetes, adolescents with type 1 diabetes, women with diabetes planning and during pregnancy. Jane is widely regarded as an authority on the development, use and interpretation of measures of psychological processes and outcomes in diabetes, also known as patient-reported outcomes (PROs).
Jane has published 150+ peer-reviewed journal articles, two books, several book chapters, and 220+ conference abstracts. Google Scholar indicates there have been >4,850 citations of her work. She has an h-index of 31 and an i10-index of 85.
Jane has been an investigator on several trials and research programme, attracting funds of $65 million, with over $60 million achieved since 2012. These include: the EU IMI2 4-year HypoRESOLVE grant (2018-2022); UK NIHR 5.5-year DAFNEplus (2016-2021); and the NHMRC 3-year GP-OSMOTIC trial (2016-2018), and the JDRF 3-year Australian Adult Hybrid Closed Loop trial (2016-2019).
T:+61 (0)3 5227 8415